ALK rearrangement

Not sure, prob ALK rearranged RCC in adult patient. (@mohant73870)

It is, actually. And I'm praying not to see this happening in my own country which is notorious for his protective social security. In fact it is already happening in oncology for those in need of new targeted therapies for rare cancers like ALK- or ROS1-rearranged NSCLCs. (@indy_yet)

A discussion on systemic therapies for patients with ALK-rearranged metastatic #NSCLC. #lcsm | @hopkinskimmel @benlevylungdoc https://t.co/6Ag2YZE4DN (@TargetedOnc)

Identification of a novel class of early exon ALK rearrangements across two pan tumor sequencing databases [2023] Leong et al. #ASCO23 Abst e15105 https://t.co/CmUi0H5mwj #lcsm #PrecisionMedicine @CSCancerCenter @TempusLabs (@mtmdphd)

Paper published 🤩📄 Study Evaluation Alectinib Pharmacokinetics in Hispanic Population with Advance ALK Rearranged NSCLC. Go and CHECK IT OUT! 🧬 Read 👉🏻 https://t.co/ZjVASPYmOL Thank you 👨🏻‍⚕️👩🏻‍⚕️@ogarrieta @LuisLara_M @YanHernandezP @DHeredia_onco @RealCaesarCas (@UToracica)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib https://t.co/JfPw0sNccf (@MLPOncoData)

🩸 Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. Q: With an 18% 12-months VTE incidence, should thromboprophylaxis be recommended upon ALK+ diagnosis? #lcsm https://t.co/Duep8S5c1a (@Tony_Calles)

It’s not really an issue of bias - simple biological plausibility. Mono-immunotherapy doesn’t / hasn’t / won’t work for EGFR mutated (& possibly ALK/ROS1 rearranged) NSCLC - that’s irrespective of what stage/indication it has been tested. Shouldn’t be attempted: that’s the tweet! (@ns_chd)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma ⁦@ESMO_Open⁩ ⁦@myESMO⁩ https://t.co/OR0vtF8PVs (@VivekSubbiah)

EGFR/ALK/ROS1 mutated/rearranged NSCLC? The suspense is killing us all… (@DrBenKong)

No...with the given immunoprofile, have to think of papillary RCC & MTSC, though cannot rule out MiTF-family tumors + ALK-rearranged RCC #kidneycancer #gupath (@rovingatuscap)

People with ALK, RET or ROS-rearranged #lungcancer often face oligoprogression - ie, disease progression in up to 5 sites even though any additional disease is under control. @Dingemans_anneM @DrSanjayPopat & Alessandra Bearz discuss the latest thinking https://t.co/nKF2oaDTu4 (@ALKpositiveINT)

Thanks for sharing the update @bensolomon1 & congratulations on leading this important trial for #ALK rearranged #NSCLC #LCSM (@ns_chd)

During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements. @hopkinskimmel @benlevylungdoc https://t.co/gYtz8b0Acl (@TargetedOnc)

WATCH: Focusing on ALK-rearranged NSCLC, expert panelists review data behind alectinib, brigatinib, and lorlatinib. @benlevylungdoc @hopkinskimmel #lcsm #oncology https://t.co/AdwxTPoALh (@OncLive)

#PostTest Q2️⃣ #TumorBoardTuesday #NSCLC 👉🏽Free #CME🔗: https://t.co/kkjEO8222z 🧐Which testing methodology is the 🥇 gold standard for detecting ALK rearrangements? (@LeciaSequist)

I must say that I’m amazed to have the opportunity to spend 2 hours discussing ALK rearranged lung cancer with Dr. @TonyMok9. I have never dreamt that someday I would have the chance to have a discussion with one of the greatest in thoracic oncology. ;) (@MarceloCorassa)

New in @DrugsinContext Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease @dmarinelli93 @marcosiringo92 @giulio_metro @BiagioMd Gelibter #drugsincontext #nsclc #oncology #lungcancer #treatment https://t.co/AyE93K3cOq (@drugsincontext)

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial https://t.co/2DVgpy5ZFP (@VivekSubbiah)

⬇️ NGS of >1400 mesotheliomas! Congrats to the authors including my @FoundationATCG colleague @EthanSokol. The rare ALK rearrangements are so tantalizing! Intrigued but less surprised to see rare KRAS G12C. Any candidate IO biomarkers here? (@geoff_oxnard)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @myESMO @ESMO_Open https://t.co/fMCw3bhfta (@VivekSubbiah)

I'm glad to see a paper like this published! AC in cancer patients is tricky, now trying to identify cancer patients at highest risk of thrombosis important (ALK/ROS rearranged NSCLC, pancreatic, IDH WT neuroblastoma, etc, ccing @connors_md)! (@LeivaOrly)

At the upcoming 23rd Annual International Lung Cancer Congress, @peters_solange, MD, PhD will be giving 2 presentations on relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged #NSCLC. #lcsm https://t.co/7Hc7QA0xHS (@TargetedOnc)

ALK as another tumor agnostic marker? MyPath pilot for alectinib. Disease control rate = 60% in ALK rearranged including PRs in colon and pancreatic and uterine leiomyosarcoma. No responses in ALK mutated or amplified (@Dr_R_Kurzrock)

⭐️Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open @myESMO https://t.co/ue8XapQp3d (@VivekSubbiah)

The crux is Rebiopsy . Had a similar case whose pd-l1 was exactly 60% ,driver mutations -ve ,put on pembro alone .Had disease progression with brain mets . Rebiopsied the patient - to find an “AlK rearrangement” .Now- PR after 1 year (@oncologician)

I was given 6 months-2yrs in 2014. Still here with Stage IV Non small cell lung cancer. Never smoker. Stable on targeted med for ALK+gene rearrangement since 2018. Get 2nd opinion. Live your life. (@DeniseMSurvivor)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/jIYAzIeWyl (@VivekSubbiah)

⭐️Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open @OncoAlert https://t.co/TC0YXLqajV (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open @myESMO https://t.co/vwAbXHjyqd (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ALKLungCancer #Targets21 https://t.co/ujnsPaD5Yp (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/dN7tjJ5Nkd (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/AnuUwlOlV7 (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/kWq2rCfO3X (@VivekSubbiah)

⭐️🔺Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/7L2psGuZHm (@VivekSubbiah)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/hIbZrIQNfx (@VivekSubbiah)

⭐️🔺Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open @myESMO #precisionmedicine @OncoAlert https://t.co/HSsf0CQNda (@VivekSubbiah)

2️⃣ different patterns of lung adenocarcinoma with concomitant EGFR mutation 🧬 and ALK rearrangement #Review by Dashi Zhao et al #lcsm @ns_chd @drgandara @filimasini @mario_pathology 🔓 https://t.co/lNYGciJEZz (@TumoriJ)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma https://t.co/VKlPSM1UWE (@VivekSubbiah)

Ceritinib in ALK rearranged lymphoma. Nice example of #multiinstitutecollaboration #benchtobedside #precisiontherapy https://t.co/74PM1VPoSw (@bmtdoc63)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open https://t.co/WWHjjZD7YZ (@VivekSubbiah)

🎯Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @myESMO @esmoopen #PrecisionMedicine https://t.co/AAz7LDlcku (@VivekSubbiah)